Position in ANNX
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$85,650
New position
Shares Held
15,000
first reported quarter
Ownership
0.007%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#159
of 214 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Derivatives in ANNX
reported options exposure · as of Jun 30, 2026CallValue
$342,600
CallShares
60,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026DLD Asset Management, LP holds $1,239,620 across 7 Biotechnology names. ANNX ranks #5 (6.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MDXG |
Mimedx Group, Inc.
|
75,000 | $288,750 | |
| 2 | INSM |
INSMED Inc
|
2,500 | $266,550 | |
| 3 | ACAD |
Acadia Pharmaceuticals Inc
|
10,000 | $253,000 | |
| 4 | IRON |
Disc Medicine, Inc.
|
3,000 | $219,420 | |
| 5 | ANNX |
Annexon, Inc.
This page
|
15,000 | $85,650 | |
| 6 | VYGR |
Voyager Therapeutics, Inc.
|
20,000 | $70,000 | |
| 7 | CTMX |
CytomX Therapeutics, Inc.
|
15,000 | $56,250 |
All Filings in ANNX
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $342,600 | 60,000 | Call | Sole | 2026-08-13 | |
| 2026-06-30 | $85,650 | 15,000 | Shares | Sole | 2026-08-13 | |
| No filing history on record for this holder in this stock. | ||||||